borderline significanceP = 0.049
The rates of other comorbid diseases, including diabetes, tumor, heart diseases, and chronic kidney disease, were not different between the 2 groups (all, P > 0.05), and the Charlson Comorbidity Index (CCI) score was higher in patients treated with ACE-I or ARB, with borderline significance (4.1 ± 1.7 vs 3.3 ± 2.4; P = 0.049).